Vascular endothelial growth factor receptors (VEGFRs) are a family of receptor protein
tyrosine kinases that play an important role in the regulation of tumor-induced angiogenesis …

When gastrointestinal stromal tumour (GIST), the most common form of sarcoma, was first
recognized as a distinct pathological entity in the 1990s, patients with advanced-stage …

Neurotrophic tropomyosin receptor kinase (NTRK) gene fusion has been identified as an
oncogenic driver of various solid tumors, and it is rare in non-smalll cell lung cancer …

Clinically acquired resistance is a major challenge in cancer therapies with small-molecule
kinase inhibitors (SMKIs). Gatekeeper mutations in the ATP-binding pocket of kinases are …

The tropomyosin receptor tyrosine kinases (TRKs) control the cell proliferation mainly in the
nervous system and are encoded by NTRK genes. Fusion and mutation of NTRK genes …

Lung cancer (LC) represents the second most diagnosed tumor and the malignancy with the
highest mortality rate. In recent years, tremendous progress has been made in the treatment …

Tropomyosin receptor kinase (TRK) secondary mutations mediating acquired resistance,
especially at the solvent-front (SF) and the DFG motif, represent an unmet clinical need …

The discovery of neurotrophic tyrosine receptor kinase (NTRK) gene fusions as pan-tumor
oncogenic drivers has led to new personalized therapies in oncology. Recent studies …

Background: Although CREB phosphorylation is known to be essential in UVB/cAMP-
stimulated melanogenesis, CREB null mice did not show identifiable pigmentation …

TRK xDFG mutation-induced acquired resistance of 1 st generation inhibitors larotrectinib
and entrectinib remains an unmet clinical need. Here we report a series of 6-(pyrrolidin-1-yl) …